

Huu Phuc Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/545454/publications.pdf>

Version: 2024-02-01

117
papers

12,039
citations

94433

37
h-index

26613

107
g-index

121
all docs

121
docs citations

121
times ranked

24804
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
3	Transgenic rat model of Huntington's disease. <i>Human Molecular Genetics</i> , 2003, 12, 617-624.	2.9	329
4	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
5	Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2008, 28, 2471-2484.	3.6	164
6	Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. <i>Journal of Neuroscience</i> , 2010, 30, 10844-10850.	3.6	136
7	Overexpression of human wildtype torsinA and human Δ^{17} GAG torsinA in a transgenic mouse model causes phenotypic abnormalities. <i>Neurobiology of Disease</i> , 2007, 27, 190-206.	4.4	123
8	Sex differences in a transgenic rat model of Huntington's disease: decreased 17β -estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. <i>Human Molecular Genetics</i> , 2008, 17, 2595-2609.	2.9	114
9	Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. <i>Human Molecular Genetics</i> , 2006, 15, 3177-3194.	2.9	109
10	Localization of sequence variations in PGC-1 β influence their modifying effect in Huntington disease. <i>Molecular Neurodegeneration</i> , 2011, 6, 1.	10.8	97
11	The regulation of OXPHOS by extramitochondrial calcium. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2010, 1797, 1018-1027.	1.0	96
12	Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. <i>Human Genetics</i> , 2010, 128, 453-459.	3.8	93
13	A Novel BACHD Transgenic Rat Exhibits Characteristic Neuropathological Features of Huntington Disease. <i>Journal of Neuroscience</i> , 2012, 32, 15426-15438.	3.6	89
14	Stem Cell Quiescence in the Hippocampal Neurogenic Niche Is Associated With Elevated Transforming Growth Factor- β Signaling in an Animal Model of Huntington Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 717-728.	1.7	86
15	Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. <i>Human Molecular Genetics</i> , 2008, 17, 1137-1146.	2.9	78
16	Cellular and subcellular localization of Huntington aggregates in the brain of a rat transgenic for Huntington disease. <i>Journal of Comparative Neurology</i> , 2007, 501, 716-730.	1.6	77
17	Impaired Regulation of Brain Mitochondria by Extramitochondrial Ca ²⁺ in Transgenic Huntington Disease Rats. <i>Journal of Biological Chemistry</i> , 2008, 283, 30715-30724.	3.4	76
18	Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. <i>Journal of Hepatology</i> , 2016, 65, 849-855.	3.7	75

#	ARTICLE	IF	CITATIONS
19	Mitochondria and Energetic Depression in Cell Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2009, 10, 2252-2303.	4.1	73
20	¹ H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1371-1379.	3.8	73
21	Generation of a novel rodent model for DYT1 dystonia. <i>Neurobiology of Disease</i> , 2012, 47, 61-74.	4.4	70
22	Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). <i>Human Molecular Genetics</i> , 2013, 22, 508-518.	2.9	70
23	Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1. <i>Human Molecular Genetics</i> , 2020, 29, 2551-2567.	2.9	69
24	Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. <i>Neurobiology of Disease</i> , 2006, 22, 538-547.	4.4	65
25	Behavioral and In Vivo Electrophysiological Evidence for Presymptomatic Alteration of Prefrontostriatal Processing in the Transgenic Rat Model for Huntington Disease. <i>Journal of Neuroscience</i> , 2011, 31, 8986-8997.	3.6	64
26	Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. <i>Human Molecular Genetics</i> , 2016, 25, ddw122.	2.9	62
27	Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. <i>Neuropharmacology</i> , 2016, 108, 24-38.	4.1	59
28	Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic rat model. <i>Behavioural Brain Research</i> , 2006, 170, 257-261.	2.2	53
29	Assessment of Motor Function, Sensory Motor Gating and Recognition Memory in a Novel BACHD Transgenic Rat Model for Huntington Disease. <i>PLoS ONE</i> , 2013, 8, e68584.	2.5	53
30	N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation. <i>Brain</i> , 2011, 134, 1925-1942.	7.6	52
31	The V471A Polymorphism in Autophagy-Related Gene ATG7 Modifies Age at Onset Specifically in Italian Huntington Disease Patients. <i>PLoS ONE</i> , 2013, 8, e68951.	2.5	49
32	Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8765-E8774.	7.1	47
33	Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: Restoration by the neuroprotective compound CEP-1347. <i>Molecular and Cellular Neurosciences</i> , 2008, 39, 1-7.	2.2	46
34	Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease. <i>Journal of Neuroscience Methods</i> , 2014, 234, 38-53.	2.5	45
35	Subtle neurological and metabolic abnormalities in an Opa1 mouse model of autosomal dominant optic atrophy. <i>Experimental Neurology</i> , 2009, 220, 404-409.	4.1	44
36	Proteasome and oxidative phosphorylation changes may explain why aging is a risk factor for neurodegenerative disorders. <i>Journal of Proteomics</i> , 2010, 73, 2230-2238.	2.4	39

#	ARTICLE	IF	CITATIONS
37	Factors influencing behavior of group-housed male rats in the social interaction test. <i>Physiology and Behavior</i> , 2001, 74, 277-282.	2.1	38
38	HBOC multi-gene panel testing: comparison of two sequencing centers. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 129-136.	2.5	38
39	Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 343-358.	4.1	38
40	A Novel Transgenic Rat Model for Spinocerebellar Ataxia Type 17 Recapitulates Neuropathological Changes and Supplies <i>In Vivo</i> Imaging Biomarkers. <i>Journal of Neuroscience</i> , 2013, 33, 9068-9081.	3.6	37
41	Early Deficits in Glycolysis Are Specific to Striatal Neurons from a Rat Model of Huntington Disease. <i>PLoS ONE</i> , 2013, 8, e81528.	2.5	37
42	Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime. <i>Molecular Neurobiology</i> , 2014, 50, 107-118.	4.0	37
43	Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat. <i>Brain</i> , 2015, 138, 3632-3653.	7.6	36
44	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic β 2-receptor levels in a transgenic Huntington's disease rat model. <i>Behavioural Brain Research</i> , 2009, 205, 175-182.	2.2	35
45	Reduction in Subventricular Zone-Derived Olfactory Bulb Neurogenesis in a Rat Model of Huntington's Disease Is Accompanied by Striatal Invasion of Neuroblasts. <i>PLoS ONE</i> , 2015, 10, e0116069.	2.5	34
46	A behavioral comparison of the common laboratory rat strains Lister Hooded, Lewis, Fischer 344 and Wistar in an automated homecage system. <i>Genes, Brain and Behavior</i> , 2014, 13, 305-321.	2.2	33
47	A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. <i>Brain</i> , 2017, 140, 1280-1299.	7.6	33
48	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. <i>Genetics in Medicine</i> , 2020, 22, 2108-2113.	2.4	32
49	Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in <i>AML</i> / <i>MDS</i> patients. <i>International Journal of Cancer</i> , 2022, 150, 1998-2011.	5.1	32
50	Neurobehavioral Tests in Rat Models of Degenerative Brain Diseases. <i>Methods in Molecular Biology</i> , 2010, 597, 333-356.	0.9	31
51	Olfactory neuron-specific expression of A30P alpha-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages. <i>Neurobiology of Disease</i> , 2011, 44, 192-204.	4.4	28
52	Impulsivity trait in the early symptomatic BACHD transgenic rat model of Huntington disease. <i>Behavioural Brain Research</i> , 2016, 299, 6-10.	2.2	25
53	Reversal Learning and Associative Memory Impairments in a BACHD Rat Model for Huntington Disease. <i>PLoS ONE</i> , 2013, 8, e71633.	2.5	24
54	Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 204.	2.0	23

#	ARTICLE	IF	CITATIONS
55	The BACHD Rat Model of Huntington Disease Shows Specific Deficits in a Test Battery of Motor Function. <i>Frontiers in Behavioral Neuroscience</i> , 2017, 11, 218.	2.0	23
56	Genotype specific age related changes in a transgenic rat model of Huntington's disease. <i>NeuroImage</i> , 2011, 58, 1006-1016.	4.2	22
57	Olesoxime in neurodegenerative diseases: Scrutinising a promising drug candidate. <i>Biochemical Pharmacology</i> , 2019, 168, 305-318.	4.4	22
58	Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia. <i>Neurobiology of Disease</i> , 2020, 134, 104634.	4.4	22
59	Automated quantitative analysis to assess motor function in different rat models of impaired coordination and ataxia. <i>Journal of Neuroscience Methods</i> , 2016, 268, 171-181.	2.5	21
60	Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats. <i>Brain Structure and Function</i> , 2013, 218, 767-778.	2.3	19
61	Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease. <i>Neuropharmacology</i> , 2018, 133, 94-106.	4.1	19
62	The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory. <i>PLoS ONE</i> , 2017, 12, e0169051.	2.5	18
63	Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond. <i>BioMed Research International</i> , 2019, 2019, 1-13.	1.9	18
64	Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18661-18669.	7.1	18
65	Cerebellar Soluble Mutant Ataxin-3 Level Decreases during Disease Progression in Spinocerebellar Ataxia Type 3 Mice. <i>PLoS ONE</i> , 2013, 8, e62043.	2.5	18
66	Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1638-1650.	1.6	17
67	Modified impact of emotion on temporal discrimination in a transgenic rat model of Huntington disease. <i>Frontiers in Behavioral Neuroscience</i> , 2013, 7, 130.	2.0	17
68	Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease. <i>Scientific Reports</i> , 2017, 7, 16880.	3.3	17
69	Polygenic Scores for Cognitive Abilities and Their Association with Different Aspects of General Intelligence—A Deep Phenotyping Approach. <i>Molecular Neurobiology</i> , 2021, 58, 4145-4156.	4.0	17
70	H3 acetylation selectively promotes basal progenitor proliferation and neocortex expansion. <i>Science Advances</i> , 2021, 7, eabc6792.	10.3	16
71	Functional changes in postsynaptic adenosine A2A receptors during early stages of a rat model of Huntington disease. <i>Experimental Neurology</i> , 2011, 232, 76-80.	4.1	15
72	Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model. <i>Journal of Genetics and Genomics</i> , 2012, 39, 287-299.	3.9	15

#	ARTICLE	IF	CITATIONS
73	Reduced Motivation in the BACHD Rat Model of Huntington Disease Is Dependent on the Choice of Food Deprivation Strategy. <i>PLoS ONE</i> , 2014, 9, e105662.	2.5	15
74	Reduced impact of emotion on choice behavior in presymptomatic BACHD rats, a transgenic rodent model for Huntington Disease. <i>Neurobiology of Learning and Memory</i> , 2015, 125, 249-257.	1.9	15
75	Mosaic Trisomy 21/Monosomy 21 in a Living Female Infant. <i>Cytogenetic and Genome Research</i> , 2009, 125, 26-32.	1.1	13
76	Dysregulation of gene expression in the striatum of BACHD rats expressing full-length mutant huntingtin and associated abnormalities on molecular and protein levels. <i>Neuropharmacology</i> , 2017, 117, 260-272.	4.1	13
77	BACHD rats expressing full-length mutant huntingtin exhibit differences in social behavior compared to wild-type littermates. <i>PLoS ONE</i> , 2018, 13, e0192289.	2.5	13
78	The calpain-suppressing effects of olesoxime in Huntington's disease. <i>Rare Diseases (Austin, Tex)</i> , 2016, 4, e1153778.	1.8	12
79	Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. <i>Neuropharmacology</i> , 2020, 162, 107812.	4.1	12
80	Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients. <i>Journal of Infectious Diseases</i> , 2022, 226, 1608-1615.	4.0	12
81	Further investigation of phenotypes and confounding factors of progressive ratio performance and feeding behavior in the BACHD rat model of Huntington disease. <i>PLoS ONE</i> , 2017, 12, e0173232.	2.5	11
82	The Guanine Nucleotide Exchange Factor Kalirin-7 Is a Novel Synphilin-1 Interacting Protein and Modifies Synphilin-1 Aggregate Transport and Formation. <i>PLoS ONE</i> , 2012, 7, e51999.	2.5	10
83	Altered reactivity of central amygdala to GABAAR antagonist in the BACHD rat model of Huntington disease. <i>Neuropharmacology</i> , 2017, 123, 136-147.	4.1	10
84	Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. <i>Scientific Reports</i> , 2018, 8, 5803.	3.3	10
85	Home-cage anxiety levels in a transgenic rat model for Spinocerebellar ataxia type 17 measured by an approach-avoidance task: The light spot test. <i>Journal of Neuroscience Methods</i> , 2018, 300, 48-58.	2.5	10
86	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. <i>BMC Cancer</i> , 2019, 19, 787.	2.6	10
87	Intranuclear immunostaining-based FACS protocol from embryonic cortical tissue. <i>STAR Protocols</i> , 2021, 2, 100318.	1.2	10
88	Sexual behavior and testis morphology in the BACHD rat model. <i>PLoS ONE</i> , 2018, 13, e0198338.	2.5	8
89	The Alteration of Emotion Regulation Precedes the Deficits in Interval Timing in the BACHD Rat Model for Huntington Disease. <i>Frontiers in Integrative Neuroscience</i> , 2018, 12, 14.	2.1	8
90	bHLH Transcription Factor Math6 Antagonizes TGF- β 2 Signalling in Reprogramming, Pluripotency and Early Cell Fate Decisions. <i>Cells</i> , 2019, 8, 529.	4.1	8

#	ARTICLE	IF	CITATIONS
91	Environmental stimulation in Huntington disease patients and animal models. <i>Neurobiology of Disease</i> , 2022, 171, 105725.	4.4	8
92	Gene expression changes in a transgenic mouse model overexpressing human wildtype and mutant torsinA. <i>Proteomics - Clinical Applications</i> , 2008, 2, 720-736.	1.6	7
93	Automated home cage assessment shows behavioral changes in a transgenic mouse model of spinocerebellar ataxia type 17. <i>Behavioural Brain Research</i> , 2013, 250, 157-165.	2.2	7
94	Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington's disease. <i>PLOS Currents</i> , 2010, 2, RRN1190.	1.4	7
95	Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients. <i>BMC Medical Genetics</i> , 2012, 13, 48.	2.1	6
96	Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 262.	5.4	6
97	Anxiety and risk assessment-related traits in a rat model of Spinocerebellar ataxia type 17. <i>Behavioural Brain Research</i> , 2017, 321, 106-112.	2.2	5
98	Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. <i>Journal of Psychopharmacology</i> , 2017, 31, 461-473.	4.0	5
99	Validation of behavioral phenotypes in the BACHD rat model. <i>Behavioural Brain Research</i> , 2020, 393, 112783.	2.2	5
100	Molecular Profiling Reveals Involvement of ESCO2 in Intermediate Progenitor Cell Maintenance in the Developing Mouse Cortex. <i>Stem Cell Reports</i> , 2021, 16, 968-984.	4.8	5
101	Normal-Weight 14-Year-Old Girl with Acanthosis Nigricans and Markedly Increased Hepatic Steatosis: Evidence for the Important Role of Ectopic Fat Deposition in the Pathogenesis of Insulin Resistance in Childhood and Adolescence. <i>Hormone Research in Paediatrics</i> , 2010, 74, 376-380.	1.8	4
102	Teaching Video NeuroImages: New STUB1 Variant Causes Chorea, Tremor, Dystonia, Myoclonus, Ataxia, Depression, Cognitive Impairment, Epilepsy, and Superficial Siderosis. <i>Neurology</i> , 2021, 97, 10.1212/WNL.0000000000012264.	1.1	4
103	DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family. <i>Brain</i> , 2022, 145, 3968-3984.	7.6	4
104	Mapping of domain-mediated protein-protein interaction by SPOT peptide assay. <i>STAR Protocols</i> , 2021, 2, 100503.	1.2	3
105	Regulation of Cell Delamination During Cortical Neurodevelopment and Implication for Brain Disorders. <i>Frontiers in Neuroscience</i> , 2022, 16, 824802.	2.8	3
106	FDG $\frac{1}{4}$ PET Fails to Detect a Disease-Specific Phenotype in Rats Transgenic for Huntington's Disease – A 15 Months Follow-up Study. <i>Journal of Huntington's Disease</i> , 2015, 4, 37-47.	1.9	2
107	Dynamic nuclear envelope phenotype in rats overexpressing mutated human torsinA protein. <i>Biology Open</i> , 2018, 7, .	1.2	2
108	The BACHD rat model of Huntington disease shows slowed learning in a Go/No-Go-like test of visual discrimination. <i>Behavioural Brain Research</i> , 2019, 359, 116-126.	2.2	2

#	ARTICLE	IF	CITATIONS
109	Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome and familial colorectal cancer type X. <i>International Journal of Cancer</i> , 2022, 150, 56-66.	5.1	2
110	Age-related alteration of emotional regulation in the BACHD rat model of Huntington disease. <i>Genes, Brain and Behavior</i> , 2020, 19, e12633.	2.2	1
111	The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease. <i>Pharmaceuticals</i> , 2021, 14, 257.	3.8	1
112	B4...Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A24.1-A24.	1.9	0
113	C6...Novel behavioural readouts of the bachd rat in the reeperbahn and barnes maze tests. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A28.3-A29.	1.9	0
114	C7...The bachd rat model of huntington's disease shows signs of fronto-striatal dysfunction in two skinner box-based tests of short-term memory. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A29.1-A29.	1.9	0
115	B05...Environment-driven influences and neuroprotection in the BACHD RAT model for huntington disease. , 2018, , .		0
116	Huntington disease update: new insights into the role of repeat instability in disease pathogenesis. <i>Medizinische Genetik</i> , 2022, 33, 293-300.	0.2	0
117	Differential Cellular Balance of Olfactory and Vomeronasal Epithelia in a Transgenic BACHD Rat Model of Huntington's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7625.	4.1	0